News

Natco Pharma Ltd share price inched up 4.07% to Rs 952.25. The Company`s net profit tanked by 47.62% to Rs 122.2 crore, while revenue from operations eased by 0.53% to Rs 735.2 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.69%. It has marginally improved by 0.66% over last one week and moving up by 11.20% in last one month while the market capitalization of Natco Pharma Ltd has improved by 3.83% and 20.49% in the same period respectively. Profit before tax (PBT) of Natco Pharma Ltd stood at Rs 185.6 crore in Q2 FY26, tumbling by 67.55% year-on-year, and surging by 28.80% quarter-on-quarter. EBITDA came in at Rs 127 crore, nosediving by 75.00% YoY and expanding by 155.62% sequentially. Total expenses slightly declined by 9.99% to Rs 595.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 157.8 crore, soaring by 53.50% YoY, while employee benefits expense was at Rs 179.3 crore, witnessing a strong rise of 13.12% YoY. For the TTM ended FY26, revenue from operations rose 10.77% to Rs 4429.5 crore, while net profit jumped 35.66% to Rs 1883.4 crore, compared to previous TTM. EBITDA jumped by 167070% to Rs 1841.5 crore, and PBT surged 36.92% to Rs 2291.4 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 1696.8 crore in FY26, as against Rs 1211.6 crore in FY25. Natco Pharma Ltd climbed 5.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.05% during the same period.

Natco Pharma Ltd. has declared an interim dividend of Rs 1.50 (75%) per equity share of Rs 2 each for the financial year 2026-27, with a record date set for August 20, 2026, and payment commencing on August 26, 2026.

Natco Pharma Limited will hold a board meeting on August 14, 2026, to consider and evaluate proposals for raising funds through the issuance of equity shares or other securities, potentially including a public issue, preferential issue, rights issue, private placement, or qualified institutions placement, subject to market conditions and regulatory approvals.

Natco Pharma will hold a meeting of the Board of Directors of the Company on 14 August 2026.

Natco Pharma announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited (Adcock Ingram), a leading South African pharmaceutical and healthcare company. With the completion of this transaction, NATCO`s shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was completed through NATCO Pharma South Africa Proprietary, NATCO`s wholly owned subsidiary in South Africa. The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around Rs 1,060 crore at the transaction exchange rate. NATCO first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram`s delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025.